Aptar Pharma is pleased to announce it is a Conference Supporter of Respiratory Drug Delivery (RDD®) 2024, taking place May 5 to 9, 2024 in Tucson, Arizona.
As a leader in respiratory drug delivery, Aptar Pharma, along with Nanopharm, an Aptar Pharma company – a leading provider of orally inhaled and nasal drug product (OINDP) design and development services and part of Aptar Pharma Services – will be showcasing their expertise and thought leadership in several ways during RDD 2024.
Experts from both companies will be on hand to demonstrate and discuss their broad portfolio of respiratory drug delivery solutions and services, including Aptar Pharma’s advances in developing sustainable pMDIs.
Aptar Pharma will also showcase their Unidose (UDS) and Bidose (BDS) nasal drug delivery systems, as well as their extensive range of pressurized Metered Dose Inhaler (pMDI) technology platforms including their DF30 Metering Valves, e-Dose Counters, Breath Actuated Inhalers (BAIs) and Dry Powder Inhalers (DPIs), all designed with the patient in mind, for the optimal treatment and management of asthma, COPD and other diseases of the lung.
Aptar Pharma Digital Health will present their expanding portfolio of connected devices to deliver digital medicines for respiratory treatments, including the HeroTracker® Sense connected add-on device for pressurized Metered Dose Inhalers (pMDIs).
As part of the RDD 2024 Workshop Presentations, on Tuesday, May 7, a 60-minute interactive workshop entitled, “SmartTrack: Combining In Vitro and In Silico Tools to De-Risk the Development of a High Payload DPI,” will be presented by William Ganley and Sara Pinto (Nanopharm), Jonathan Mulpas (Aptar Pharma) and Irene Rossi (Harro).
Four scientific posters will be presented by Aptar Pharma and Nanopharm during the RDD 2024 Poster and Exhibition Sessions, which will take place on Monday, May 6 and Tuesday, May 7 from 11:30 AM to2:30 PM and 5:00 PM to 7:00 PM:
- Physiologically Based Modeling to Design an Inhaled Powder Formulation of Imipenem that Maximizes the Lung Lining Fluid Dose, presented by Will Ganley (Nanopharm)
- Leachables Assessment from a New Generation of pMDIs Using Low Global Warming Potential Propellants and The Impact of Ethanol Filling, presented by Pauline Fauchard (Aptar Pharma)
- Optimization of a Multidose Nasal Actuator Targeting Olfactory Region Deposition, presented by Gonçalo Farias (Aptar Pharma)
- Comparative Assessment of Plume Velocity in pMDI Solutions: A Study Using PDA System and SprayView Analysis, presented authored by Lucas Silva (Nanopharm).
The RDD conference series is recognized as one of the premier international meetings in the respiratory field, impacting regulatory and scientific policies worldwide. Aptar Pharma, as a long-time supporter of RDD conferences, looks forward to be returning to this year’s event, to meet with industry experts and delegates, and to share perspective on the latest trends in the field of respiratory and nasal drug delivery.
To register for Respiratory Drug Delivery (RDD®) 2024, visit www.rddonline.com.
